US equities
|
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SPCX
$147.49
▲+0.00%
SNDK
$1,238.03
▲+0.00%
NU
$15.16
▲+0.00%
NVDA
$210.96
▲+0.00%
NBIS
$158.74
▲+0.00%
AAPL
$347.73
▲+0.00%
MU
$877.55
▲+0.00%
TSLA
$372.22
▲+0.00%
SPCX
$147.49
▲+0.00%
SNDK
$1,238.03
▲+0.00%
NU
$15.16
▲+0.00%
NVDA
$210.96
▲+0.00%
NBIS
$158.74
▲+0.00%
AAPL
$347.73
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by AVEO Oncology
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
December 01, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
November 10, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
November 08, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
November 01, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
September 20, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
August 30, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
July 29, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
July 08, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
June 07, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
May 25, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
May 19, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
May 19, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
April 16, 2021
From
AVEO Oncology
Via
Business Wire
Tickers
AVEO
